|By PR Newswire||
|April 8, 2014 01:59 PM EDT||
LONDON, April 8, 2014 /PRNewswire/ --
The trading session on Monday, April 07, 2014 ended on a lower note as the S&P 500 finished the session 1.08% lower at 1,845.04 and the NASDAQ Composite closed at 4,079.75, down 1.16%. The Dow Jones Industrial Average finished at 16,245.87, down 1.02%. During the session, nine out of ten sectors ended the session in negative. The S&P 500 Health Care Sector Index finished the day at 664.68, down 1.06%, and the same has declined 2.85% in the previous three trading sessions. Investor-Edge has initiated coverage on the following equities: Sanofi (NYSE: SNY), Impax Laboratories Inc. (NASDAQ: IPXL), Keryx Biopharmaceuticals Inc. (NASDAQ: KERX) and Rigel Pharmaceuticals Inc. (NASDAQ: RIGL). Free technical research on SNY, IPXL, KERX and RIGL can be downloaded upon signing up at:
On Monday, Sanofi's stock advanced 1.15%, to close the day at $51.82. The stock recorded a trading volume of 3.26 million shares as compared with its three months average volume of 1.81 million shares. The stock oscillated between $51.28 and $51.93 during the trading session. Sanofi's stocks have fallen by 0.38% in the previous three trading sessions, 0.21% in the last one month, and 3.37% on YTD basis. The stock is trading above its 50-day and 200-day moving averages. Sanofi's 200-day moving average of $51.05 is above its 50-day moving average of $50.53. Moreover, shares of the company have a Relative Strength Index (RSI) of 49.51. Sign up today to read free research on SNY at:
Shares in Impax Laboratories Inc. reported a trading volume of 0.87 million shares, as compared with its three months average volume of 0.58 million shares. The stock ended the day at $23.81, up 0.89% and at an intraday range of $23.02 and $24.38. Impax Laboratories Inc.'s shares have declined 9.26% in the previous three trading sessions, 13.26% in the last one month, and 5.29% on YTD basis. Shares of the company traded at a PE ratio of 24.67. The stock is trading above its 200-day moving average. Impax Laboratories Inc.'s 50-day moving average of $25.10 is above its 200-day moving average of $22.53. Furthermore, the shares of the company have an RSI of 36.39. Sign up today to read free research on IPXL at:
On Monday, Keryx Biopharmaceuticals Inc.'s stock finished the session 0.75% lower at $15.80. A total of 2.60 million shares were traded, which is below its three months average volume of 3.24 million shares. The stock fluctuated between $15.29 and $16.54 during the session. Keryx Biopharmaceuticals Inc.'s stock have plummeted 7.22% in the previous three trading sessions, while the same has advanced 3.47% in the last one month, and 22.01% on YTD basis. The stock is trading above its 50-day and 200-day moving averages. Keryx Biopharmaceuticals Inc.'s 50-day moving average of $15.65 is above its 200-day moving average of $11.87. Moreover, shares of the company have an RSI of 50.81. Sign up today to read free research on KERX at:
Shares in Rigel Pharmaceuticals Inc.'s registered a trading volume of 1.37 million shares, as compared with its three months average volume of 0.97 million shares. The stock ended the day at $3.49, down 1.69% after vacillating between $3.35 and $3.60. Rigel Pharmaceuticals Inc.'s shares have declined 8.40% in the previous three trading sessions, 22.79% in the last one month, but the same has gained 22.46% on YTD basis. The stock is trading above its 200-day moving average. Rigel Pharmaceuticals Inc.'s 50-day moving average of $3.68 is above its 200-day moving average of $3.39. Additionally, shares of the company have an RSI of 39.80. Sign up today to read free research on RIGL at:
1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is fact checked and produced on a best efforts basis and reviewed by Namrata Maheshwari, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.investor-edge.com.
5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.investor-edge.com.
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.investor-edge.com for consideration.
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Investor-edge. An outsourced research services provider represented by Namrata Maheshwari, CFA, has only reviewed the information provided by Investor-edge in this article or report according to the Procedures outlined by Investor-edge. Investor-edge is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Investor-edge makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Investor-edge is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Investor-edge whatsoever for any direct, indirect or consequential loss arising from the use of this document. Investor-edge expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Investor-edge does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.